RecruitingPhase 1NCT06556732

Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patients With Structural Heart Disease

Potential Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patients With Structural Heart Disease

Sponsor

Assiut University

Enrollment

100 participants

Start Date

Aug 10, 2024

Study Type

INTERVENTIONAL

Conditions

Atrial Fibrillation

Summary

This is a prospective comparative study, conducted at Cardiology Department, Aswan University Hospital on AF patients with structural heart disease. Eplerenone 25 mg daily will be given and searching for AF recurrence among study population.

Eligibility

Min Age: 20 YearsMax Age: 70 Years

Inclusion Criteria1

Patients with non-valvular AF who underwent cardioversion to sinus rhythm either medical, electrical or even spontaneously

Exclusion Criteria9

Patients with rheumatic heart disease.
Thyroid dysfunction.
Wolf-Parkinson-White (WPW) syndrome.
Renal impairment.
Hyperkalemia.
Acute coronary syndrome.
Pregnancy.
Left ventricular (LV) dysfunction with ejection fraction (EF) less than 40%.
On current use of eplerenone.

Interventions

DRUGEplereone

Group A (study group): 50 patients received eplerenon 25 mg daily plus amiodarone and other medications not including non-dihydropyridine calcium channel blocker or digoxin.